White Knight Strategic Wealth Advisors LLC Purchases Shares of 14,391 Novo Nordisk A/S $NVO

White Knight Strategic Wealth Advisors LLC acquired a new position in Novo Nordisk A/S (NYSE:NVO) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 14,391 shares of the company’s stock, valued at approximately $732,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in NVO. Godfrey Financial Associates Inc. acquired a new position in shares of Novo Nordisk A/S in the fourth quarter worth about $25,000. WealthCollab LLC grew its position in shares of Novo Nordisk A/S by 93.5% during the 4th quarter. WealthCollab LLC now owns 538 shares of the company’s stock valued at $27,000 after acquiring an additional 260 shares during the period. American National Bank & Trust acquired a new stake in shares of Novo Nordisk A/S during the 4th quarter valued at about $28,000. Jackson Grant Investment Advisers Inc. purchased a new position in shares of Novo Nordisk A/S in the 4th quarter valued at about $29,000. Finally, Maseco LLP purchased a new position in shares of Novo Nordisk A/S in the 4th quarter valued at about $29,000. Institutional investors and hedge funds own 11.54% of the company’s stock.

Analysts Set New Price Targets

NVO has been the subject of a number of analyst reports. Morgan Stanley raised Novo Nordisk A/S from an “underweight” rating to an “equal weight” rating and set a $40.00 price target for the company in a report on Tuesday, March 3rd. Zacks Research upgraded Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research report on Tuesday, March 10th. JPMorgan Chase & Co. restated a “neutral” rating on shares of Novo Nordisk A/S in a research report on Tuesday, February 24th. Wolfe Research initiated coverage on Novo Nordisk A/S in a research note on Thursday, March 26th. They set a “peer perform” rating for the company. Finally, Wall Street Zen upgraded Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research report on Saturday, May 16th. Four analysts have rated the stock with a Buy rating, eighteen have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $65.56.

Trending Headlines about Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Wegovy’s oral tablet is gaining traction in the U.K. and could provide Novo Nordisk with an early European launch path, which may help support future growth as it expands beyond injections. Article Title
• Positive Sentiment: Bank of America data indicates oral Wegovy is already accounting for roughly one-third of all Wegovy prescriptions, suggesting strong adoption and continued momentum in Novo Nordisk’s weight-loss franchise. Article Title
• Neutral Sentiment: Brokerages continue to rate Novo Nordisk as a “Hold,” reinforcing a wait-and-see view as the company balances growth opportunities against mounting operational and competitive pressures. Article Title
• Negative Sentiment: Novo Nordisk confirmed a security incident involving stolen clinical trial data after hackers reportedly demanded a $25 million ransom and began leaking information, raising concerns about data security, regulatory exposure, and reputational damage. Article Title

Novo Nordisk A/S Stock Down 0.7%

NVO stock opened at $43.20 on Friday. Novo Nordisk A/S has a 52 week low of $35.12 and a 52 week high of $74.38. The company has a quick ratio of 0.56, a current ratio of 0.79 and a debt-to-equity ratio of 0.59. The firm has a 50-day simple moving average of $42.81 and a 200-day simple moving average of $45.86. The stock has a market capitalization of $192.89 billion, a P/E ratio of 10.14, a P/E/G ratio of 3.89 and a beta of 0.78.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings results on Tuesday, March 31st. The company reported $1.03 earnings per share for the quarter. Novo Nordisk A/S had a net margin of 37.23% and a return on equity of 63.31%. The firm had revenue of $10.85 billion for the quarter. Equities analysts forecast that Novo Nordisk A/S will post 3.45 earnings per share for the current fiscal year.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.